Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CLPT

CLPT - ClearPoint Neuro Inc Stock Price, Fair Value and News

5.71USD+0.05 (+0.88%)Market Closed

Market Summary

CLPT
USD5.71+0.05
Market Closed
0.88%

CLPT Stock Price

View Fullscreen

CLPT RSI Chart

CLPT Valuation

Market Cap

156.6M

Price/Earnings (Trailing)

-7.59

Price/Sales (Trailing)

5.98

Price/Free Cashflow

-12.63

CLPT Price/Sales (Trailing)

CLPT Profitability

Operating Margin

57.10%

Return on Equity

-59.64%

Return on Assets

-38.45%

Free Cashflow Yield

-7.92%

CLPT Fundamentals

CLPT Revenue

Revenue (TTM)

26.2M

Rev. Growth (Yr)

40.6%

Rev. Growth (Qtr)

12.17%

CLPT Earnings

Earnings (TTM)

-20.6M

Earnings Growth (Yr)

26.08%

Earnings Growth (Qtr)

10.24%

Breaking Down CLPT Revenue

Last 7 days

-0.5%

Last 30 days

-5.0%

Last 90 days

-20.1%

Trailing 12 Months

-18.7%

How does CLPT drawdown profile look like?

CLPT Financial Health

Current Ratio

3.14

Debt/Equity

0.29

Debt/Cashflow

-1.19

CLPT Investor Care

Shares Dilution (1Y)

11.55%

Diluted EPS (TTM)

-0.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202426.2M000
202321.0M21.7M22.3M24.0M
202217.3M19.1M19.7M20.6M
202113.7M14.7M15.7M16.3M
202011.9M11.7M12.3M12.8M
20198.2M9.2M10.3M11.2M
20187.0M6.7M6.8M7.4M
20176.4M7.2M7.3M7.4M
20163.7M4.4M5.1M5.7M
20152.8M1.7M2.3M3.0M
20143.5M4.1M3.8M2.6M
20135.3M4.8M4.6M3.9M
20124.0M4.4M4.4M5.1M
20113.0M3.2M3.5M3.8M
20100002.7M
20090002.6M

Tracking the Latest Insider Buys and Sells of ClearPoint Neuro Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
d'alessandro danilo
sold (taxes)
-27,689
5.74
-4,824
chief financial officer
Jun 10, 2024
stigall l. jeremy
sold (taxes)
-14,361
5.74
-2,502
chief business officer
Jun 10, 2024
burnett joseph michael
sold (taxes)
-80,377
5.74
-14,003
ceo and president
May 14, 2024
girin pascal e r
acquired
-
-
17,153
-
May 14, 2024
richards timothy t.
acquired
-
-
17,153
-
May 14, 2024
fallon lynnette c
acquired
-
-
17,153
-
May 14, 2024
johnson b kristine
acquired
-
-
17,153
-
May 14, 2024
klein matthew b.
acquired
-
-
34,306
-
May 14, 2024
liau linda m.
acquired
-
-
34,306
-
May 14, 2024
fletcher r john
acquired
-
-
17,153
-

1–10 of 50

Which funds bought or sold CLPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
sold off
-100
-87,000
-
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-38.93
-77,316
121,760
-%
May 16, 2024
AWM Investment Company, Inc.
new
-
893,731
893,731
0.12%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.91
-9,945
15,674
-%
May 15, 2024
STATE STREET CORP
added
19.31
461,660
2,830,680
-%
May 15, 2024
D. E. Shaw & Co., Inc.
new
-
282,982
282,982
-%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-25.68
-3,678
10,703
-%
May 15, 2024
Sentinus, LLC
new
-
101,796
101,796
0.04%
May 15, 2024
Manatuck Hill Partners, LLC
new
-
510,000
510,000
0.22%
May 15, 2024
POM Investment Strategies, LLC
unchanged
-
-
102
-%

1–10 of 48

Are Funds Buying or Selling CLPT?

Are funds buying CLPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CLPT
No. of Funds

Unveiling ClearPoint Neuro Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.32%
1,308,694
SC 13G
Feb 06, 2024
bigger capital, llc
3.5%
868,042
SC 13G/A
Jan 29, 2024
blackrock inc.
6.0%
1,470,056
SC 13G
Jun 15, 2023
ptc therapeutics, inc.
9.76%
2,561,245
SC 13D/A
Feb 09, 2023
bigger capital fund l p
3.0%
746,994
SC 13G/A
Jan 26, 2022
bigger capital fund l p
2.8%
655,690
SC 13G/A
Jun 09, 2021
bigger capital fund l p
2.8%
575,484
SC 13G
Mar 02, 2021
ptc therapeutics, inc.
14.00%
2,961,245
SC 13D/A
Feb 11, 2021
satterfield thomas a jr
4.0%
720,000
SC 13G/A
Feb 13, 2020
satterfield thomas a jr
7.8%
1,225,000
SC 13G/A

Recent SEC filings of ClearPoint Neuro Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading

Peers (Alternatives to ClearPoint Neuro Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.0B
40.3B
-0.56% 0.17%
31.97
4.46
-2.84% -3.00%
67.0B
19.7B
-1.30% -8.44%
50.29
3.4
4.82% -17.56%
20.4B
3.9B
-2.39% -15.83%
44.2
5.22
5.72% 46.72%
17.2B
14.9B
-4.28% -22.37%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-1.42% 26.61%
30.88
2.73
6.16% 35.06%
8.5B
12.4B
-8.96% -11.44%
21.86
0.68
-0.93% -18.83%
8.0B
2.6B
-4.13% -24.00%
-24.93
3.09
-6.25% -68.58%
5.5B
3.9B
-5.09% -29.87%
-58.03
1.41
0.23% 90.80%
3.4B
387.1M
-0.21% 32.29%
-215.53
8.87
30.82% 65.57%
2.0B
6.6B
-10.10% -15.73%
10.59
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
18.01% 16.23%
-2.22
0.48
7.94% -1695.32%
385.1M
169.3M
1.48% -3.53%
-5.01
2.28
7.49% -244.90%
248.7M
324.0M
0.65% -42.87%
-1.29
0.77
-3.19% -337.41%
50.6M
50.5M
3.55% -78.84%
-2.22
1
14.25% -10.06%
1.8M
3.7M
-17.65% -79.41%
-0.15
0.49
5.77% 8.23%

ClearPoint Neuro Inc News

Latest updates
Yahoo Movies UK26 hours ago

ClearPoint Neuro Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue12.2%7,6396,8105,7625,9505,4335,1745,1465,2005,0314,2824,5743,4134,0303,7163,5192,4783,1163,2112,9272,6062,473
Cost Of Revenue11.3%3,1142,7972,4892,8242,2311,8081,4671,9451,8001,0931,5331,1391,4161,0739038029321,0429831,030886
Gross Profit12.8%4,5254,0133,2733,1263,2023,3663,6793,2553,2313,1893,0412,2742,614-2,6161,676-----
  S&GA Expenses4.4%2,8412,7202,9003,1782,9582,3762,3982,6612,1761,9312,4361,9821,6571,5281,2521,2141,2761,3121,0301,028933
  R&D Expenses-1.0%2,6252,6522,4293,6053,0232,9282,6542,4112,9013,0412,6012,1091,5631,9131,143812818766762698585
Interest Expenses22.0%11191.0010081.0011484.0032.00-91.00-1061,211-238240332204201197842229213259254
Income Taxes----------------------
Net Income10.2%-4,146-4,619-4,809-7,052-5,609-4,385-3,788-4,303-3,959-4,149-3,980-3,743-2,538-1,582-1,484-1,661-2,055-1,645-1,122-1,550-1,220
Net Income Margin14.5%-0.79*-0.92*-0.98*-0.96*-0.86*-0.80*-0.82*-0.86*-0.92*-0.88*-0.75*-0.64*---------
Free Cashflow-224.8%-3,800-1,170-2,080-5,398-5,818-3,104-3,921-5,057-4,338-3,590-3,421-3,683---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets25.7%54.0043.0044.0048.0050.0055.0058.0060.0062.0066.0069.0072.0074.0030.0022.0023.0024.0012.0013.0013.008.00
  Current Assets31.5%48.0036.0037.0041.0046.0051.0054.0057.0058.0062.0065.0069.0070.0025.0020.0021.0022.0010.0012.0012.006.00
    Cash Equivalents53.0%35.0023.0024.0027.0022.0028.0019.0024.0050.0054.0058.0062.0065.0020.0015.0016.0017.006.006.007.002.00
  Inventory0.6%8.008.009.009.0010.009.008.007.006.005.004.004.003.003.004.004.004.003.003.003.002.00
  Net PPE-3.0%1.001.001.001.001.001.001.001.001.001.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities-11.3%19.0021.0020.0020.0018.0019.0018.0017.0016.0017.0025.0024.0030.0027.0022.0022.0021.007.007.006.007.00
  Current Liabilities104.0%15.007.006.006.006.007.006.005.004.005.005.004.003.003.004.004.004.004.004.003.002.00
  Long Term Debt-10.00-------------1.001.00-----
Shareholder's Equity63.3%35.0021.0024.0027.0033.0037.0040.0043.0046.0049.0044.0048.0044.002.000.001.003.005.006.007.000.00
  Retained Earnings-2.4%-176-172-167-163-155-150-145-142-137-133-130-126-122-119-117-116-114-112-111-109-108
  Additional Paid-In Capital9.1%211193192190188187186185183182174174166122118118117117117117109
Shares Outstanding11.2%27.0025.0025.0025.0025.0025.0024.0024.0024.0024.0021.0020.00---------
Float----155---272---361---43.00---43.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-230.7%-3,800-1,149-1,796-5,075-5,680-3,065-3,852-4,981-4,269-3,552-3,296-3,718-2,131-2,401-1,367-1,708-2,331-466-964-810-609
  Share Based Compensation-2.5%1,5041,5431,5841,6451,3071,1721,175880899925586247320328293241228223219204153
Cashflow From Investing100.0%--188-2359,510-13811,746-631-21,666-185-38.00-12535.00-40.00-41.00---441190*-10.19--
Cashflow From Financing10256.8%16,053155-91.00237-5.00222-3295133.0048.00-45234946,9307,876-76414,052-72.93-252--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CLPT Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 7,639$ 5,433
Cost of revenue3,1142,231
Gross profit4,5253,202
Research and development costs2,6253,023
Sales and marketing expenses3,2902,933
General and administrative expenses2,8412,958
Operating loss(4,231)(5,712)
Other expense:  
Other expense, net(26)(11)
Interest income, net111114
Net loss$ (4,146)$ (5,609)
Net loss per share attributable to common stockholders:  
Basic (in dollars per share)$ (0.16)$ (0.23)
Diluted (in dollars per share)$ (0.16)$ (0.23)
Weighted average shares used in computing net loss per share:  
Basic (in shares)25,452,09624,583,163
Diluted (in shares)25,452,09624,583,163
Product revenue  
Revenue:  
Total revenue$ 3,635$ 2,630
Service and other revenue  
Revenue:  
Total revenue$ 4,004$ 2,803

CLPT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 35,353$ 23,140
Accounts receivable, net2,5113,211
Inventory, net7,9607,911
Prepaid expenses and other current assets1,7461,910
Total current assets47,57036,172
Property and equipment, net1,3471,389
Operating lease, right-of-use assets3,4473,564
Software license inventory237386
Licensing rights8871,041
Other assets149109
Total assets53,63742,661
Current liabilities:  
Accounts payable844393
Accrued compensation1,6342,947
Other accrued liabilities9861,053
Operating lease liabilities, current portion497424
Deferred product and service revenue, current portion1,2322,613
2020 senior secured convertible note payable, net9,9640
Total current liabilities15,1577,430
Operating lease liabilities, net of current portion3,4383,568
Deferred product and service revenue, net of current portion458541
2020 senior secured convertible note payable, net09,949
Total liabilities19,05321,488
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.01 par value; 90,000,000 shares authorized at March 31, 2024 and December 31, 2023; 27,416,345 shares issued and outstanding at March 31, 2024; and 24,652,729 issued and outstanding at December 31, 2023274247
Additional paid-in capital210,912193,382
Accumulated deficit(176,602)(172,456)
Total stockholders’ equity34,58421,173
Total liabilities and stockholders’ equity$ 53,637$ 42,661
CLPT
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain. It has license and collaboration agreements with Clinical Laserthermia Systems AB, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
 CEO
 WEBSITEclearpointneuro.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES108

ClearPoint Neuro Inc Frequently Asked Questions


What is the ticker symbol for ClearPoint Neuro Inc? What does CLPT stand for in stocks?

CLPT is the stock ticker symbol of ClearPoint Neuro Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ClearPoint Neuro Inc (CLPT)?

As of Thu Jun 13 2024, market cap of ClearPoint Neuro Inc is 156.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLPT stock?

You can check CLPT's fair value in chart for subscribers.

What is the fair value of CLPT stock?

You can check CLPT's fair value in chart for subscribers. The fair value of ClearPoint Neuro Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ClearPoint Neuro Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ClearPoint Neuro Inc a good stock to buy?

The fair value guage provides a quick view whether CLPT is over valued or under valued. Whether ClearPoint Neuro Inc is cheap or expensive depends on the assumptions which impact ClearPoint Neuro Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLPT.

What is ClearPoint Neuro Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, CLPT's PE ratio (Price to Earnings) is -7.59 and Price to Sales (PS) ratio is 5.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ClearPoint Neuro Inc's stock?

In the past 10 years, ClearPoint Neuro Inc has provided 0.208 (multiply by 100 for percentage) rate of return.